BETHESDA, Md., Sept. 16, 2016 /PRNewswire-USNewswire/ -- The ACMG Foundation for Genetic and Genomic Medicine has recently published translations of ACMG's Phenylalanine Hydroxylase Deficiency (PKU) Practice Guidelines in Spanish, French, Turkish, German, Portuguese (Br) and Italian. All six translated guidelines are available online.
In an effort to reach international providers and patients, BioMarin Pharmaceutical Inc., a corporate sponsor of the ACMG Foundation, supported this translation project in order to ensure global access and readability of these important practice guidelines for the treatment of patients with PKU. BioMarin Pharmaceutical Inc. focuses on therapeutics for rare diseases.
Michael S. Watson, PhD, FACMG, executive director of the American College of Medical Genetics and Genomics said, "Translation of ACMG's PKU guidelines will help expand international access to the practice guideline which will assist providers in delivering accurate and reliable information. No professional organization better encompasses the global view of the genome and the experience and mindset to apply genomic information more broadly to maintain health and diagnose and treat disease, than ACMG."
About the ACMG Foundation
The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics in healthcare. Established in 1992, the ACMG Foundation for Genetic and Genomic Medicine supports the American College of Medical Genetics and Genomics' mission to "translate genes into health" by raising funds to attract the next generation of medical geneticists and genetic counselors, to sponsor important research, to promote information about medical genetics, and much more.
To learn more about the important mission and projects of the ACMG Foundation for Genetic and Genomic Medicine and how you, too, can support this great cause, please visit www.acmgfoundation.org or contact us at [email protected] or 301/718-2014.
Kathy Ridgely Beal, MBA
SOURCE ACMG Foundation for Genetic and Genomic Medicine